OpenEvidence and the Rise of AI Doctors

Artificial intelligence is rapidly transforming the healthcare industry, and one of the clearest signs of that shift came when medical AI startup OpenEvidence announced a new funding round that doubled the company’s valuation to an extraordinary $12 billion. The Miami-based company, often described as “ChatGPT for doctors,” has quickly become one of the fastest-growing and most closely watched startups in healthcare technology.

The company recently secured $250 million in fresh funding led by Thrive Capital and DST Global. The financing round comes less than a year after OpenEvidence was valued at just $1 billion, underscoring the explosive investor enthusiasm surrounding AI-powered medical tools.

“If you only squint from a distance, OpenEvidence is ‘ChatGPT’ for doctors. If you look closely, it’s a very different organism.” — Daniel Nadler, OpenEvidence founder

The startup’s rapid ascent reflects a much broader trend taking place across medicine. Hospitals, physicians, insurers and healthcare systems are increasingly embracing artificial intelligence tools designed to improve diagnostics, summarize medical literature, reduce administrative burden and help doctors make faster clinical decisions.

The Rise of Medical AI

OpenEvidence was founded in 2022 by Daniel Nadler, a billionaire entrepreneur who previously sold Kensho Technologies to Standard & Poor’s for $700 million, along with co-founder Zachary Ziegler, a former Harvard PhD student focused on artificial intelligence research.

Unlike general-purpose AI chatbots, OpenEvidence was built specifically for physicians and healthcare professionals. The company trains its AI systems using highly specialized medical literature and scientific journals, including partnerships with major publications such as the New England Journal of Medicine.

Doctors Begin Integrating AI Into Clinical Practice

Recent reporting from Massachusetts highlighted how physicians are already experimenting with AI-assisted diagnostics in real-world clinical settings. Some doctors are using AI systems to help identify overlooked conditions, summarize patient histories and cross-reference medical research during difficult cases.

Supporters believe AI could eventually reduce diagnostic errors, accelerate treatment planning and improve access to medical expertise in underserved areas.

Healthcare represents nearly 20% of the U.S. economy, making it one of the largest long-term opportunities for artificial intelligence.

Healthcare represents nearly $5 trillion in annual spending in the United States, yet many hospitals and clinics still rely on fragmented software systems and highly manual workflows. AI companies believe that can change dramatically over the next decade.

The Competitive Race Intensifies

OpenAI, Anthropic, Google and Microsoft are all expanding aggressively into healthcare-focused AI products. OpenAI has reportedly launched HIPAA-compliant healthcare offerings, while Anthropic introduced Claude Healthcare.

Nearly every major AI company now appears to view medicine as one of the most commercially attractive long-term sectors for generative AI. The reason is simple: healthcare combines massive spending with severe inefficiencies and overwhelming information complexity.

At the same time, hospitals and physicians are increasingly open to adopting AI tools because workforce shortages and burnout continue pressuring healthcare systems nationwide.

Data and Physician Networks Become Strategic Assets

Nadler argues that OpenEvidence possesses an important competitive advantage because it has accumulated vast amounts of physician interaction data and real-world clinical usage patterns.

“We’ve already gathered hundreds of millions of real-world clinical consultations from verified physicians.” — Daniel Nadler

AI systems often improve through reinforcement, feedback and real-world interaction, meaning platforms with large physician networks could potentially strengthen their lead over newer entrants.

According to the company, approximately 95% of new users hear about the platform from other doctors, highlighting how peer trust remains critically important in healthcare adoption.

Concerns Around Safety and Regulation

Despite the excitement, many physicians remain cautious. Critics worry that AI systems could hallucinate inaccurate medical information, introduce hidden bias or create legal and ethical complications around liability.

Questions surrounding patient privacy also remain especially important. Healthcare data is among the most sensitive information in the digital economy, and AI systems handling patient records must comply with strict HIPAA requirements and cybersecurity protections.

Regulators are still determining how medical AI tools should be governed, audited and integrated into clinical workflows.

The Future of AI-Assisted Medicine

OpenEvidence’s growth suggests many investors believe AI-assisted medicine could eventually become one of the largest software opportunities in healthcare history. Some analysts compare the current moment to the early rise of electronic health records or cloud computing adoption in medicine.

The company’s business model also stands out. Unlike many AI startups that rely primarily on subscription fees, OpenEvidence reportedly generates significant revenue through advertising while keeping the platform free for doctors.

For now, OpenEvidence says it plans to remain independent despite growing consolidation across the AI industry. Larger technology firms have been aggressively acquiring AI startups in an effort to secure talent, data and specialized industry expertise.

Artificial intelligence is no longer viewed merely as an experimental tool for medicine. It is increasingly becoming part of the daily workflow of healthcare itself.

Whether OpenEvidence ultimately becomes an independent public company or an acquisition target remains uncertain. But its rapid rise already signals something much larger taking place across healthcare and technology.